From the CMS report “Medicare Drug Worth Negotiation Program: Decided on Medication for Preliminary Worth
Applicability 12 months 2027“:

On January 17, 2025, CMS introduced the number of the underneath listing of 15 medicine coated below Medicare Section D for the second one cycle of negotiations (preliminary worth applicability yr 2027), in response to overall gross coated prescription drug prices below Medicare Section D and different standards as required by means of the regulation.

With the Trump inauguration to happen on Monday, will the Medicare Drug Worth Negotiation procedure exchange with the brand new management? Anna Kaltenboeck notes in EndPoints Information:

…the following management won’t have “blanket authority to switch the core portions of the regulation,” sure facets of the method may also be modified with out legislative motion.

For instance, CMS may just adjust its steerage or the way it translates portions of the regulation, comparable to how again and again it meets with drugmakers, or what number of listening periods it holds. “The stage to which they play hardball with producers within the procedure may just exchange,” she mentioned.